ÓÍÍÆÄÃϵÁÐ-ÓÍÍÆÄÃϵÁг§¼Ò¡¢Æ·ÅÆ¡¢Í¼Æ¬¡¢ÈÈÌû-°¢Àï°Í°Í"/> ÔÚÁ½¶Ó½ü 6 ´Î½»·æÖУ¬°¢Ë¹¶ÙάÀ 2 ʤ 2 ƽ 2 ¸º£¬Ë«·½ÊƾùÁ¦µÐ£¬×î½üÒ»´Î¶Ô¾öÒÔ 1-1 սƽ¡£Î¬À½ü 10 ³¡Î´³¢Æ½ÊÖ£¨5 ʤ 5 ¸º£©£¬²®¶÷é˹½ü 10 ³¡Æ½ÊÖ¶à´ï 5 ³¡£¬Õ½ÊõÆø¸Å²î±ðÏÔ×Å¡£²®¶÷é˹Ö÷³¡¶ÔÕóάÀÔøÁ½´Î±¬À䣨2022 Äê 2-0¡¢2020 Äê 2-1£©£¬µ«Î¬À±¾Èü¼¾¿Í³¡Ê¤ÂÊ 42.9% ¸ßÓÚ²®¶÷é˹Ö÷³¡Ê¤ÂÊ 33.3%£¬Î¬ÀÔÚÐÄÀíÉÏÓÐÒ»¶¨ÓÅÊÆ¡£"/>
¡¶ÓÍÍÆÄÃϵÁÐ-ÓÍÍÆÄÃϵÁг§¼Ò¡¢Æ·ÅÆ¡¢Í¼Æ¬¡¢ÈÈÌû-°¢Àï°Í°Í¡·¾çÇé¼ò½é£ºÔÚÁ½¶Ó½ü 6 ´Î½»·æÖа¢Ë¹¶ÙάÀ 2 ʤ 2 ƽ 2 ¸ºË«·½ÊƾùÁ¦µÐ×î½üÒ»´Î¶Ô¾öÒÔ 1-1 սƽάÀ½ü 10 ³¡Î´³¢Æ½ÊÖ£¨5 ʤ 5 ¸º£©²®¶÷é˹½ü 10 ³¡Æ½ÊÖ¶à´ï 5 ³¡Õ½ÊõÆø¸Å²î±ðÏÔ×Ų®¶÷é˹Ö÷³¡¶ÔÕóάÀÔøÁ½´Î±¬À䣨2022 Äê 2-0¡¢2020 Äê 2-1£©µ«Î¬À±¾Èü¼¾¿Í³¡Ê¤ÂÊ 42.9% ¸ßÓÚ²®¶÷é˹Ö÷³¡Ê¤ÂÊ 33.3%άÀÔÚÐÄÀíÉÏÓÐÒ»¶¨ÓÅÊÆºß´ËµØÎ£ÏÕÖ®¼«ÎÒÄĹ˵ÃÉÏÕâЩÄãÈôÊDz»Ïë×ß¾¡¿É»ØÈ¥Ä½Èݸ´ÀäÉù»ØÊÖµÀËûÕâ°ãһ˵µ¹Ç¡ËÆÊÜÁËʲô¼«´óµÄίÇüÒ»ÑùÓÍÍÆÄÃϵÁÐ-ÓÍÍÆÄÃϵÁг§¼Ò¡¢Æ·ÅÆ¡¢Í¼Æ¬¡¢ÈÈÌû-°¢Àï°Í°Í¿´×ÅÀÞ̨ÉÏ·½º®ºÍÍòÁ¬É½µÄ½»ÊÖ½¹·ÉɨÁËÒ»ÑÛÔÚ³¡ÓÐ×ʸñÉÏÀÞ̨µÄÏÉħÁ½µÀѧÉúµ¹ÊǰÑÑÛ¹âÍ£ÁôÔÚÁËħ˧ÉíÉÏǩԼ³ªÆ¬¹«Ë¾ºóÞ±æ«Ò²ÍƳöÁ˼¸Ê×µ¥ÇúÊÂÒµÉú³¤µÄ»¹²»´íÐ¡ÖøÃûÆø
¡¶ÓÍÍÆÄÃϵÁÐ-ÓÍÍÆÄÃϵÁг§¼Ò¡¢Æ·ÅÆ¡¢Í¼Æ¬¡¢ÈÈÌû-°¢Àï°Í°Í¡·ÊÓÆµËµÃ÷£º°ëÌìÖ®ºóËûÃÇÔÚÒ»×ùÑÒѨÖÐÍ£ÁËÏÂÀ´³þÐÛÖÝË«°ØÏØ¿ÖÁúºÓ×ÔÈ»±£»¤ÇøÂÌ¿×ȸÔÚ½øÊ³æÒÏ·»ÆÐËÄÜ ÉãÕã½¶¦Á¦´ó¾Ù(603338)8ÔÂ17ÈÕÍí¼äÅû¶°ëÄ걨ÉϰëÄ깫˾ʵÏÖÓªÒµÊÕÈë30.98ÒÚԪͬ±ÈÔöÌí5.23%£»¾»ÀûÈó8.32ÒÚԪͬ±ÈÔöÌí44.87%£»»ù±¾Ã¿¹ÉÊÕÒæ1.64Ôª
Ñ©ºúÀÏ׿µãò¥Ê׳ÁÉùµÀ£ºÕâÒ»´ÎÊÇÎÒÍдóÁËÔ±¾ÍýÏë¾ÙÐеúÜ˳ËìÏɽ©Ä¹µØÏÕЩ±»ÎÒÒ»Íø´ò¾¡Ð§¹ûͻȻ·ÉÀ´Ò»Î»Ñ×»ÍÀ×ÔóÏɽ©Õâ¿ÉÊÇÄ¥Á¶ºèÔ˹ÆÉϼѵÄÏɲÄÎÒ¼ûÁÔÐÄϲ±ãÍÑÊÖ×½ÄÃûÏëµ½¶Ô·½ÔúÊÖÔÚŵØÖиüÔç¾Í°²ÅÅÁ˹ÆÕóÎÒ´óÒâÖ®ÏÂÕÚÑÚ²»×¡Õ½¶·µÄÉùÏ쾪¶¯Á˱±Ô½©ÃË#¶È¼Ù´©´î #Æø·Õ¸ÐÕÕÏà #ÏÄÈÕʱÉÐ
¹Ë¥ʧÉùËÆµÄ[4]Mair MJ, Bartsch R, Le Rhun E, et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. Nat Rev Clin Oncol. 2023;20(6):372-389. doi:10.1038/s41571-023-00756-z
2025-10-18 11:31:46